Characterization of a new myeloid leukemia cell line with normal cytogenetics (CG-SH)

Leukemia Research

Volumn 33, Issue 10, 2009, Pages 1405-1408

  Munker, Reinhold ^a,b   Nordberg, Mary Lowery ^a,b   Veillon, Diana ^a   Williams, B Jill ^a,b   Roggero, Anthony ^a   Kern, Wolfgang ^c   Dicker, Frank ^c   Haferlach, Torsten ^c  

^a Louisiana State University School of Medicine Shreveport   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

AML; Cell line; Normal cytogenetics

Indexed keywords

CD133 ANTIGEN; CD135 ANTIGEN; CD15 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CD7 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB ALPHA; HLA DR ANTIGEN; MICRORNA; MICROSOMAL AMINOPEPTIDASE; MYELOPEROXIDASE; RAS PROTEIN; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL MATURATION; CELL STRAIN CG SH; CONTROLLED STUDY; CYTOGENETICS; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; HETEROZYGOTE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ANTIGENS, CD; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; CORE BINDING FACTOR ALPHA 2 SUBUNIT; CYTOGENETIC ANALYSIS; CYTOKINES; GENES, RAS; HLA ANTIGENS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOID; LEUKEMIA, MYELOID, ACUTE; MICRORNAS; MUTATION; PHENOTYPE; REFERENCE VALUES; RNA, NEOPLASM;

EID: 67649311629     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.04.008     Document Type: Article

References (19)

1. Lübbert M., and Koeffler H.P. Myeloid cell lines: tools for studying differentiation of normal and abnormal hematopoietic cells. Blood Rev 2 (1988) 121-133
2. Drexler H.G., Matsuo A.Y., and MacLeod R.A. Continuous hematopoietic cell lines as model systems for leukemia-lymphoma research. Leuk Res 24 (2000) 881-911
3. Schoch C., Kern W., Kohlmann A., Hiddemann W., Schnittger S., and Haferlach T. Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalance and a specific gene expression profile. Genes Chromos Cancer 43 (2005) 227-238
4. Dicker F., Haferlach C., Kern W., Haferlach T., and Schnittger S. Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. Blood 110 (2007) 1308-1316
5. Bacher U., Haferlach C., Kern W., Haferlach T., and Schnittger S. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters- an analysis of 3082 patients. Blood 111 (2008) 2527-2537
6. Haferlach T., Kohlmann A., Schnittger S., Dugas M., Hiddemann W., Kern W., et al. Global approach to the diagnosis of leukemia using gene expression profiling. Blood 106 (2005) 1189-1198
7. Drexler HG. Guide to leukemia-lymphoma cell lines (E-book), Braunschweig; 2005.
8. Kawano-Yamamoto C., Muroi K., Nagatsuka K., Higuchi M., Kikuchi S., Nagai T., et al. Establishment and characterization of a new erythroblastic leukemia cell line EEB: Phosphatidylglucoside-mediated erythroid differentiation and apoptosis. Leuk Res 30 (2006) 829-839
9. Chang H., Salma F., Yi Q.L., Patterson B., Brien B., and Minden M.D. Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukaemia. Leuk Res 28 (2004) 43-48
10. Beauchemin V., Villeneuve L., Rodriguez-Cimadevilla J.C., Rajotte D., Kenney J.S., Clark S.C., et al. Interleukin-6 production by the blasts of acute myeloblastic leukemia: regulation by endogenous interleukin-1 and biological implications. J Cell Physiol 148 (1991) 353-361
11. Baldus C.D., Mrózek K., and Marcucci G. Bloomfield CD Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review. Br J Haematol 137 (2007) 387-400
12. Radich J.P., Kopecky K.J., Wilman C.L., Weick J., Head D., Appelbaum F., et al. N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance. Blood 76 (1990) 801-807
13. Ritter M., Kim T.D., Lisske P., Thiede C., Schaich M., and Neubauer A. Prognostic significance of N-RAS and K-RAS mutations in 232 patients with acute myeloid leukemia. Haematologica 89 (2004) 1397-1399
14. Niimi H., Harada H., Harada Y., Ding Y., Imagawa J., Inaba T., et al. Hyperactivity of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations. Leukemia 20 (2006) 635-644
15. Motoda L., Osato M., Yamashita N., Jacob B., Chen L.Q., Yanagida M., et al. Runx1 protects hematopoietic stem/progenitor cells from oncogenic insult. Stem Cells 25 (2007) 2976-2986
16. Vegesna V., Takeuchi S., Hofmann W.K., Ikezoe T., Tavor S., Krug U., et al. C/EBP-β, C/EBP-δ, PU.1 AML1 genes: mutational análysis in 381 samples of hematopoietic and solid malignancies. Leuk Res 26 (2002) 451-457
17. Fujisaki H., Takai K., Sawada A., Tokimasa S., Matsuda Y., Ohta H., et al. Establishment of a monosomy 7 leukemia cell line, MONO-7, with a ras gene mutation. Int J Hematol 75 (2002) 72-77
18. Marcucci G., Maharry K., Radmacher M.D., Mrózek K., Vukosavljevic T., Paschka P., et al. Prognostic significance of, and gene and microRNA expression signatures associated with CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B study. J Clin Oncol 31 (2008) 5078-5087
19. Garzon R., Volinia S., Liu C.G., Fernandez-Cymering C., Palumbo T., Pichiorri F., et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 111 (2008) 3183-3189